Literature DB >> 22858269

Role of mitral valve plication in the surgical management of hypertrophic cardiomyopathy.

Sandhya K Balaram1, Ronald E Ross, Mark V Sherrid, Gary S Schwartz, Zak Hillel, Glenda Winson, Daniel G Swistel.   

Abstract

BACKGROUND: We have previously reported our 3-step repair for obstructive hypertrophic cardiomyopathy (HCM) consisting of resection of the septum, horizontal plication of the anterior mitral leaflet (AML), and release of abnormal papillary muscle attachments. This article reviews our complete experience with surgical management of HCM to better understand the role and relevance of mitral plication.
METHODS: From 1997 to 2011, 132 patients with HCM underwent surgical treatment at our institution. Eighty-two patients (62%) received AML plication based on selection criteria and were classified as group A; patients in group B did not receive plication. All patients underwent preoperative and postoperative echocardiography. Long-term clinical follow-up was obtained by review of scheduled echocardiograms and direct patient interview.
RESULTS: The average age of all patients was 55.5 years. Operative mortality was 0%. The mean left ventricular outflow tract (LVOT) gradient decreased from 118±41 mm Hg to 6±13 mm Hg (p<0.0001). Mean mitral regurgitation improved from 2.4±1.0 to 0.5±0.7 (p<0.0001). Postoperatively, 96.2% of patients had no residual systolic anterior motion (SAM). Significant improvements in heart failure classification and quality of life scores were noted for all patients. Comparison of groups A and B showed no statistically significant differences in outcomes, complications, or survival. Survival at 1, 5, and 10 years was 98%, 98%, and 92%, respectively.
CONCLUSIONS: The heterogeneity of the pathologic process in HCM supports detailed analysis of the septum, mitral leaflets, and subvalvular apparatus. Surgical management of HCM that includes horizontal plication of a lax and elongated AML is safe and results in durable clinical and echocardiographic improvement.
Copyright © 2012 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22858269     DOI: 10.1016/j.athoracsur.2012.06.008

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  17 in total

1.  Alcohol septal ablation: in which patients and why?

Authors:  Paolo Spirito; Jessica Rossi; Barry J Maron
Journal:  Ann Cardiothorac Surg       Date:  2017-07

2.  Long-term outcome of simultaneous septal myectomy and anterior mitral leaflet retention plasty in hypertrophic obstructive cardiomyopathy: the Berlin experience.

Authors:  Eva Maria Delmo Walter; Mariano Francisco Javier; Roland Hetzer
Journal:  Ann Cardiothorac Surg       Date:  2017-07

Review 3.  The surgical management of obstructive hypertrophic cardiomyopathy: the RPR procedure-resection, plication, release.

Authors:  Daniel G Swistel; Mark V Sherrid
Journal:  Ann Cardiothorac Surg       Date:  2017-07

Review 4.  Surgical treatment for hypertrophic cardiomyopathy: a historical perspective.

Authors:  Dustin Hang; Anita Nguyen; Hartzell V Schaff
Journal:  Ann Cardiothorac Surg       Date:  2017-07

5.  The Role of Cardiac MRI in the Diagnosis and Risk Stratification of Hypertrophic Cardiomyopathy.

Authors:  Ethan J Rowin; Martin S Maron
Journal:  Arrhythm Electrophysiol Rev       Date:  2016

6.  Minimally invasive trans-mitral septal myectomy for diffuse-type hypertrophic obstructive cardiomyopathy.

Authors:  Taichi Sakaguchi; Toshinori Totsugawa; Kentaro Tamura; Arudo Hiraoka; Genta Chikazawa; Hidenori Yoshitaka
Journal:  Gen Thorac Cardiovasc Surg       Date:  2018-03-16

Review 7.  Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy.

Authors:  Daniel J Philipson; Eugene C DePasquale; Eric H Yang; Arnold S Baas
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

8.  Outcomes of an extended Morrow procedure without a concomitant mitral valve procedure for hypertrophic obstructive cardiomyopathy.

Authors:  Yun Liu; Yunhu Song; Ge Gao; Jun Ran; Wenjun Su; Haojie Li; Yajie Tang; Fujian Duan; Hansong Sun
Journal:  Sci Rep       Date:  2016-06-30       Impact factor: 4.379

9.  Long-term clinical and echocardiographic outcomes of extensive septal myectomy for hypertrophic obstructive cardiomyopathy in Chinese patients.

Authors:  Lei Yao; Li Li; Xiong-Jun Lu; Yan-Ling Miao; Xiao-Ning Kang; Fu-Jian Duan
Journal:  Cardiovasc Ultrasound       Date:  2016-05-17       Impact factor: 2.062

Review 10.  Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice.

Authors:  Mark V Sherrid
Journal:  Curr Cardiol Rev       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.